Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969695 · ClinicalTrials.gov registry record · Phase 1

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

A Phase 1 study, sponsored by AbbVie.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target

NCT01969695: Completed Phase 1 study, sponsored by AbbVie.

NCT01969695 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969695, a Phase 1 study, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target

Study Summary

This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.

Primary Outcome

Electrocardiogram and Multi Gated Acquisition Scan and/or Echocardiogram

Interventions

  • DRUG ABT-199

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2013-12-20
Est. Completion 2019-12-16
Phase Phase 1
AbbVie

526 total trials

What the finished NCT01969695 record still lists

NCT01969695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 1 intervention - of which ABT-199 is the first listed.

NCT01969695 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01969695 about?

NCT01969695 is a clinical study titled "An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma". This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 w...

What is the current status of trial NCT01969695?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-12-20. Estimated completion is 2019-12-16.

What interventions are being tested in trial NCT01969695?

The interventions under investigation include: ABT-199 (DRUG).

Who is sponsoring clinical trial NCT01969695?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01969695's enrollment target sits among peer trials

11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01969695, the US trial registry maintained by the National Library of Medicine. NCT01969695 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.